BBS-Bioactive Bone Substitutes Oyj - Asset Resilience Ratio
BBS-Bioactive Bone Substitutes Oyj (BONEH) has an Asset Resilience Ratio of 15.58% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how BBS-Bioactive Bone Substitutes Oyj's Asset Resilience Ratio has changed over time. Check BONEH strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BBS-Bioactive Bone Substitutes Oyj's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BBS-Bioactive Bone Substitutes Oyj (BONEH) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.67 Million | 15.58% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.67 Million | 15.58% |
Asset Resilience Insights
- Good Liquidity Position: BBS-Bioactive Bone Substitutes Oyj maintains a healthy 15.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BBS-Bioactive Bone Substitutes Oyj Industry Peers by Asset Resilience Ratio
Compare BBS-Bioactive Bone Substitutes Oyj's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic PLC
XETRA:2M6 |
Medical Devices | 7.91% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Aroa Biosurgery Ltd
AU:ARX |
Medical Devices | 12.13% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
MICROPORT CARDIO.MEDTECH.
F:72X |
Medical Devices | 37.03% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
Annual Asset Resilience Ratio for BBS-Bioactive Bone Substitutes Oyj (2015–2022)
The table below shows the annual Asset Resilience Ratio data for BBS-Bioactive Bone Substitutes Oyj.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.19% | €1.52 Million ≈ $1.77 Million |
€10.69 Million ≈ $12.50 Million |
+2.43pp |
| 2021-12-31 | 11.76% | €1.24 Million ≈ $1.45 Million |
€10.51 Million ≈ $12.28 Million |
-15.32pp |
| 2020-12-31 | 27.09% | €3.44 Million ≈ $4.02 Million |
€12.69 Million ≈ $14.84 Million |
+27.09pp |
| 2016-12-31 | 0.00% | €-499.00 ≈ $-583.38 |
€12.80 Million ≈ $14.97 Million |
+0.00pp |
| 2015-12-31 | 0.00% | €-499.00 ≈ $-583.38 |
€12.45 Million ≈ $14.56 Million |
-- |
About BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more